- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Biodesix GAAP EPS of -$0.07 beats by $0.01, revenue of $18.2M misses by $0.32M | 1 | Seeking Alpha | ||
| Fr | Biodesix, Inc.: Biodesix Announces Third Quarter 2024 Results and Highlights | 51 | GlobeNewswire (Europe) | Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast... ► Artikel lesen | |
| 24.09. | Farallon Capital Management LLC Purchases New Stake in Biodesix, Inc. (NASDAQ:BDSX) | 1 | MarketBeat | ||
| 15.08. | BIODESIX INC - 8-K, Current Report | - | SEC Filings | ||
| 13.08. | Biodesix executive sells over $300 in stock, prices range $1.52 to $1.64 | 1 | Investing.com | ||
| 13.08. | Biodesix exec sells over $680 in stock, automatic sale for taxes | 1 | Investing.com | ||
| 13.08. | Biodesix CEO Scott Hutton sells shares worth over $5,900 | 1 | Investing.com | ||
| 13.08. | Biodesix CFO sells over $1,500 in company stock | 1 | Investing.com | ||
| 13.08. | Biodesix executive sells shares worth $740 amid automatic tax-related sale | 1 | Investing.com | ||
| 08.08. | Earnings call: Biodesix reports robust growth and raises 2024 guidance | 1 | Investing.com | ||
| 07.08. | Biodesix Inc reports results for the quarter ended in June - Earnings Summary | 1 | Reuters | ||
| 07.08. | Biodesix GAAP EPS of -$0.08 beats by $0.01, revenue of $17.9M beats by $1.76M | 1 | Seeking Alpha | ||
| 07.08. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | Biodesix Announces Second Quarter 2024 Results and Highlights | 85 | Business Wire | LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June... ► Artikel lesen | |
| 24.05. | BIODESIX INC - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 23.05. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 10.05. | Earnings call: Biodesix outlines robust Q1 growth, targets profitability in 2024 | 1 | Investing.com | ||
| 08.05. | BIODESIX INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.05. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management | 74 | Business Wire | LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PAION | 0,010 | -22,73 % | Schock-News für Paion Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| EPIGENOMICS | 0,900 | +12,50 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,357 | -6,30 % | Defence Therapeutics Inc.: Defence Therapeutics Completes 1st Tranche of Financing | Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 7,150 | 0,00 % | Lesaffre strengthens its Research, Development & Innovation (RD&I) with the acquisition of Altar, a company owned by Ginkgo Bioworks | MARCQ-EN-BARŒUL, France, Oct. 7, 2024 /PRNewswire/ -- Lesaffre, a key global player in the field of fermentation and microorganisms, announces the acquisition of Altar, a French start-up... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,435 | +1,82 % | Recursion Pharmaceuticals-Direktor Blake Borgeson verkauft Aktien im Wert von 76.926 US-Dollar | ||
| GUARDANT HEALTH | 20,010 | -5,75 % | Guardant Health, Inc.: Guardant Health to Participate in Upcoming Investor Conferences | Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences.
Guggenheim Inaugural Healthcare... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,800 | +3,78 % | Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results | U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients Enrolled and Six Patients Dosed... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 1,080 | +1,89 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study | Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study
Together, these two studies support the compelling potential of pelareorep-based... ► Artikel lesen | |
| ASSERTIO | 1,040 | +0,97 % | Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | LAKE FOREST, Ill., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 17,790 | +0,34 % | CSL And Arcturus Therapeutics Announce Japanese Approval For Updated Self-amplifying MRNA COVID-19 Vaccine | CANBERA (dpa-AFX) - Australian biotechnology company CSL Ltd. (CSL.AX, CSLLY.PK) and sa-mRNA pioneer Arcturus Therapeutics, announced Friday that Japan's Ministry of Health, Labor and Welfare... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 7,260 | +0,55 % | SIGA Technologies Inc.: SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results | ||
| ADMA BIOLOGICS | 19,245 | +18,00 % | ADMA Biologics jumps as KPMG becomes new auditor | ||
| VIR BIOTECHNOLOGY | 9,160 | +22,30 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,800 | +1,22 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
BIODESIX INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -24,41 % bei einem Aktienkurs von 1,285 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.
